Drug Development Pharma - March 24, 2025
New findings about Elypta’s urine test in kidney cancer follow-up
Elypta has announced that findings from the international AURORAX-0087A (AUR87A) study, the largest diagnostics study ever conducted on the most common type of kidney cancer, were presented today in a Plenary Game Changer Session at the 2025 European Association of Urology Congress.
Agreement - March 24, 2025
Novo Nordisk and the United Laboratories in license agreement for a GLP-1/GIP/glucagon triple receptor agonist
Novo Nordisk and the United Laboratories International Holdings Limited (TUL)'s wholly-owned subsidiary The United Bio-Technology have entered into an exclusive license agreement for UBT251, a triple agonist of the receptors for GLP-1, GIP, and glucagon in early-stage clinical development for the treatment of obesity, type 2 diabetes, and other diseases.
Global report - March 21, 2025
AstraZeneca to invest USD 2.5 billion in R&D centre in Beijing
AstraZeneca is establishing a new global strategic R&D centre in Beijing, its second in China and sixth worldwide.
Biotech Business - March 21, 2025
Alligator Bioscience announces FDA Orphan Drug designation
The U.S. Food and Drug Administration (FDA) has granted Orphan Drug Designation (ODD) to HLX22 (AC101), an anti-HER2 monoclonal antibody, for the treatment of gastric cancer.
Finland - March 20, 2025
New medtech pilot environment established in Finland
VTT Technical Research Centre of Finland has opened a new pilot line environment for medical devices in Oulu, Finland.
Acquisition - March 20, 2025
Xbrane in agreement to sell biosimilar candidate and parts of its organization to Alvotech
Xbrane Biopharma has entered into an agreement to sell XB003 (biosimilar candidate to Cimzia) and parts of its organization, including approximately 40 employees and laboratory equipment, to Alvotech for a total consideration of approximately SEK 275 million.
